Edwin Posadas MD FACP KM

PubMed

• Shared Decision-Making for Advanced Renal Cell Carcinoma: Focus on Adverse Event Management of Axitinib Plus IO: A Vodcast.
  Edwin M Posadas, Nancy Moldawer, Greg Biddulph, Dharanija Rao
  Oncology and Therapy. 2025-04-02
• CD105 blockade restores osimertinib sensitivity in drug-resistant EGFR-mutant non-small cell lung cancer.
  Manish Thiruvalluvan, Sandrine Billet, Zhenqiu Liu, Joseph Lownik, Barliz Waissengrin
  Drug Resistance Updates. 2025-03-12
• Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity that Associates with a Clinically Aggressive Subtype of Prostate Cancer.
  Le Zhang, Pai-Chi Teng, Karen A Cavassani, Jasmine Wang, Catherine Grasso
  Clinical Cancer Research. 2025-03-10

Journal Articles

• Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer  
  Tagawa ST, Posadas EM, Bruce J, Lim EA, Petrylak DP, Peng W, Kheoh T, Maul S, Smit JW, Gonzalez MD, De Porre P, Tran N, Nanus DM, Eur Urol., 1/3/2016
• Increased survival with enzalutamide in prostate cancer after chemotherapy  
  Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hains..., N Engl J Med, 1/1/2012
• Presurgical Therapy for Renal Cell Carcinoma and Implications for Window of Opportunity Trials  
  Kim, H.L., Posadas, E.M., Figlin RA, Renal Cell Carcinoma: Biology, Prognostic Factors, and Therapeutic targets, 1/1/2011
• Chemotherapy for Central Nervous System Metastases in Renal Cancer: A Review  
  Chen, T., Posadas, E., Lukas, R., Kidney Cancer Journal, 1/1/2011
• Frontiers in Prostate Cancer: Telomeres and Cancer  
  Sommerfeld, H.J., Meeker, A.K., Posadas, E.M., Coffey, D.S., Cancer, 1/1/1995
• Synthesis and characterization of putrescinebased poly(phosphoester-urethanes)  
  Dahiyat, B. I., Hostin, E., Posadas, E. M. and Leong, K. W, Journal of biomaterials science, 1/1/1993
• Antiandrogen therapy in prostate cancer  
  Szmulewitz, R.Z., Posadas, E.M., Update on Cancer Therapeutics
• Join now to see all

Books/Book Chapters

• Principles and Practices of Oncology 
  Chapter: Molecular Biology of Prostate Cancer 
  Feng, F.Y., Chinnayan, A., Posadas, E.M.Editors: DeVita, Hellman, Rosenberg.2014
• Drug Management of Prostate Cancer. 
  Chapter: Calcitriol and Vitamin D analogs 
  Jensen, A.R., Szmulewitz, R.Z., Beer, T., Posadas, E.M.Editors: W. Figg and E. Small.2010
• Prostate Cancer: A Clinical Guide 
  Chapter: Management of Prostate Cancer Bone Metastases 
  Szmulewitz, R.Z., Posadas, E.M.Lippincott Williams & Wilkins2008
• Oncology-Hematology Source Book: Evidence-Based Principles 
  Chapter: Bladder Cancer 
  Posadas, E.M., Dahut WLEditors: Boyiadzis, Lebowitz, Frame, Fojo.Edition 1st,2007
• The Molecular Oncology of Prostate Cancer 
  Chapter: Angiogenesis and Angiogenesis Inhibitors 
  Posadas, E.M., Dahut WLEditors: J Ross, C Foster, Jones and Bartlett.2006
• Bethesda Handbook of Clinical Oncology 
  Chapter: Cervical Cancer 
  Posadas, E.M., Kotz, H.Edition 2nd,2005
• Proteomics in Cancer Research 
  Chapter: Protein arrays for clinical proteomics and signal transduction profiling. 
  Simpkins, F., Espina, V., Posadas, E., Petricoin, E., Liotta, L., Kohn ECEditors: D.C. Liebler.2005
• Principles and Practice of Gynecologic Oncology 
  Chapter: Chapter 4: tumor angiogenesis and metastasis 
  Posadas, E.M., Kohn ECEditors: W. Hoskins.Edition 4th,
• Join now to see all

Abstracts/Posters

• A phase 2 study of BIND-014 (PSMA-targeted docetaxel nanoparticle) administered to patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mC...
  Autio KA, Garcia JA, Alva AS, Hart LL, Milowsky MI, Posadas EM, Ryan CJ, Summa JM, Youssoufian H, Scher HI, Dreicer R, J Clin Oncol, 1/1/2016
• A phase II study of cabozantinib in metastatic castration-resistant prostate cancer (mCRPC) with visceral metastases (VM) with very small nuclear circulating tumor cel...
  Huynh R, Chen JF, Tighiouart M, Sievert M, Oppenheim A, Moldawer NP, Knudsen B, Freeman M, Bhomowmick N, Rogatko A, Tseng HR, Cheng LWK, Scher K, Figlin RA, Posadas EM, J Clin Oncol, 1/1/2016
• Very small nuclear circulating tumor cell (vsnCTC) as a putative biomarker for visceral metastasis in metastatic castration-resistant prostate cancer (mCRPC)
  Chen JF, Ho H, Hodara E, Go A, Ureno A, Kaufman ET, Sievert M, Chung LWK, Ke Z, Tseng HR, Posadas EM, J Clin Oncol, 1/1/2016
• Subclassification of prostate cancer circulating tumor cells (CTCs) by nuclear size reveals very-small nuclear CTCs in patients with visceral metastases.
  Lu YT, Chen JF, Ho H, Lichterman J, Chung LWK, Li KC, Ke Z, Tseng HR, Posadas EM, J Clin Oncol, 1/1/2015
• Phase 1b study of ARN-509 with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
  Posadas EM, Chi KN, De Wit R, Jonge MJ, Attard G, Friedlander TW, Yu MK, Hellemans, P, Chien C, Abrams CC, Gonzalez M, Trudel GC, Chauhan V, Jiao JJ, Saad F, J Clin Oncol, 1/1/2015
• Sub-classification of prostate cancer circulating tumor cells (CTCs) by nuclear size reveals very-small nuclear CTCs in patients with visceral metastases
  Chen JF, Ho H, Lichterman J, Lu YT, Zhang Y, Garcia MA, Chen SF, Zhau H, Hous S, Ahmed RA, Luthringer DJ, Huang J, Li KC, Chung LWK, Ke Z, Tseng HR, Posadas EM, AACR, 1/1/2015
• Pharmacokinetics (PK) and safety of ARN-509 with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castrationresistant prostate cancer (mCR...
  Posadas EM, Chi KN, De Wit R, Jonge MJ, Attard G, Friedlander TW, Yu MK, Hellemans, P, Chien C, Abrams CC, Gonzalez M, Trudel GC, Chauhan V, Jiao JJ, Saad F., AACR, 1/1/2015
• A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma.
  Choueiri TK, Michaelson MD, Posadas EM, Sonpavde G, McDermott DF, Walsh MK, Wall KC, Seon BK, Jivani MA, Adams BJ, Theuer CP, J Clin Oncol, 1/1/2015
• Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
  Tagawa ST, Posadas EM, Bruce J, Lim EA, Petrylak DP, Ping W, Kheoh T, Maul S, Smit JW, Gonzalez MD, Deporre P, Tran N, Nanus DM, J Clin Oncol, 1/1/2014
• Biologic activity of dasatinib administered as neoadjuvant therapy preceding radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC).
  NM Hahn, S Daneshmand, EM Posadas, MO Koch, R Bihrle, R Foster, TA Masterson, L Cheng, Z Liu, T Breen, MT Fleming, R Lance, CW Ryan, CL Corless, MD Galsky, A Shivaram ..., J Clin Oncol, 1/1/2014
• A phase 1b dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC).
  Choueiri TK, Michaelson MD, Posadas EM, Sonpavde G, McDermott DF, Walsh MK, Wall KC, Seon BK, Jivani MA, Adams BJ, Theuer CP., J Clin Oncol, 1/1/2014
• A translational phase 2 study of cabozantinib in men with metastatic castration resistant prostate cancer with visceral metastases with characterization of circulating...
  Posadas EM, Tighiouart M, Lu Y, Di Vizio D, Hoffman DJ, Green L, Scher K, Sievert M, Oppenheim A, Moldawer N, Knudsen B, Freeman M, Bhowmick N, Rogatko A, Tseng HR, Ch..., J Clin Oncol, 1/1/2014
• A translational phase 2 study of cabozantinib in men with metastatic castration resistant prostate cancer with visceral metastasis with characterization of circulating...
  Posadas EM, Tighiouart M, Lu Y, Di Vizio D, Hoffman DJ, Green L, Scher K, Sievert M, Oppenheim A, Moldawer N, Knudsen B, Freeman M, Bhowmick N, Rogatko A, Tseng HR, Ch..., Annals of Oncology, 1/1/2014
• A phase II trial of neoadjuvant dasatinib (Neo-D) in muscle-invasive urothelial carcinoma of the bladder (miUCB): Hoosier Oncology Group GU07-122 trial
  NM Hahn, S Daneshmand, EM Posadas, MO Koch, R Bihrle, R Foster, TA Masterson, L Cheng, Z Liu, T Breen, MT Fleming, R Lance, CW Ryan, CL Corless, MD Galsky, A Shivaram ..., J Clin Oncol, 1/1/2012
• Phase II trial of linifanib in patients (pts) with advanced renal cell carcinoma (RCC): Analysis of pts receiving extended therapy.
  Posadas EM, Tannir NM, Wong Y, Ernstoff MS, Kollmannsberger CK, Qian J, Ansell PJ, McKeegan EM, McKee MD, Ricker JL, Carlson DM, Michaelson MD, J Clin Oncol, 1/1/2011
• A randomized phase II study of pazopanib in castrate-sensitive prostate cancer: A University of Chicago phase II consortium/DoD Prostate Cancer Clinical Trials Consort...
  Ward JE, Karrison, T, Chatta G, Hussain M, Shevrin D, O'Donnell P, Szmulewitz RZ, Stadler WM, Posadas EM., J Clin Oncol, 1/1/2011
• Phase II study of AT-101 to abrogate Bcl-2-mediated resistance to androgen-deprivation therapy (ADT) in patients (pts) with newly diagnosed androgen-dependent metastat...
  Stein MN, I. Khan, M. Hussain, G. Liu, G. Wilding, Posadas EM, Stadler WM, C. Jeyamohan, S. Eddy, R. S. DiPaola, J Clin Oncol, 1/1/2011
• Fluorescence-activated cell sorting (FACS) and immunofluorescence (IF) detection and characterization of circulating tumor cells (CTC) from men with castrate-resistant...
  Szmulewitz RZ, A. J. Wyche, Posadas EM, Stadler WM, J Clin Oncol, 1/1/2011
• A randomized, double-blind, placebo-controlled phase II study of testosterone replacement in men with asymptomatic castrate-resistant prostate cancer (PC).
  Szmulewitz RZ, Posadas EM, B. Manchen, Stadler WM, J Clin Oncol, 1/1/2010
• Tannir NM, Y. Wong, C. K. Kollmannsberger, M. S. Ernstoff, D. J. Perry, L. J. Appleman, Posadas EM, J. Qian, J. L. Ricker, D. Michaelson.
  Tannir NM, Y. Wong, C. K. Kollmannsberger, M. S. Ernstoff, D. J. Perry, L. J. Appleman, Posadas EM, J. Qian, J. L. Ricker, D. Michaelson., J Clin Oncol, 1/1/2010
• Transient metastasis suppression by JNKK1/MKK4 in an experimental model of prostate cancer metastasis.
  Szmulewitz RZ, Tamara Lotan, Jennifer Taylor, Kristen Otto, Edwin M. Posadas, Carrie W. RinkerSchaeffer., Proceedings of the 100th Annual Meeting of the American Association for Cancer Research, Denver, CO, 2009; Philadelphia, PA, 2009, 1/18/2009
• FYN knockdown results in altered cell morphology and motility in prostate cancer
  Saito YD., Jensen, A.R., Otto, K., Faoro, L., Jagadeeswaran, R., Salgia, R., Posadas EM, Proceedings of the 100th Annual Meeting of the American Association for Cancer Research, Denver, CO, 2009; Philadelphia, PA, 2009, 1/18/2009
• A phase II trial of gemcitabine (G), capecitabine I and bevacizumab (B) in patients with metastatic renal cell carcinoma (RCC).
  Chung EK, Posadas EM, T. Karrison, E. Manchen, L. Michalak, O. M. Hahn, Stadler WM., Genitourinary Cancers Symposium., 1/1/2009
• as EM, S. Culine, M. Carducci, G. Trudel (for the Research & Development, BMS), C. Sternberg. A phase II study of once-daily dasatinib for patients with castration-res...
  Yu E, C. Massard, M. Gross, G. Wilding, Posadas EM, S. Culine, M. Carducci, G. Trudel (for the Research & Development, BMS), C. Sternberg., Genitourinary Cancers Symposium, 1/1/2009
• A phase II trial of gemcitabine(G), capecitabine I, and bevacizumab (B) in patients (pts) with metastatic renal cell carcinoma (RCC).
  Chung EK, Posadas EM, K. Kasza, T. Karrison, E. Manchen, L. Michalak, O. M. Hahn, Stadler WM., J Clin Oncol, 1/1/2009
• Join now to see all

Lectures

• Intermittent vs. Continuous Androgen Deprivation Therapy 
  Ho Chi Minh City/Hanoi, Vietnam - 1/14/2016
• Blood-based biomarkers and precision oncology 
  Samuel Oschin Comprehensive Cancer Institute. Los Angeles, CA - 1/10/2016
• Circulating tumor cells versus circulating tumor DNA 
  Los Angeles, CA - 1/23/2015
• Immunotherapy of Genitourinary Malignancies. 
  Los Angeles, CA - 1/19/2015
• Urologic Oncology for OCNs 
  1/18/2015
• Advances in Medical Therapy for Prostate Cancer 
  Charles Drew University. - 1/12/2015
• Molecular Targets in Kidney and Bladder Cancer. 
  1/7/2015
• Targeted therapy in Renal Cell Carcinoma. 
  1/7/2015
• Advancing Paradigms in Systemic Therapy for prostate cancer 
  1/5/2015
• Circulating tumor cell nuclear sizes predict visceral metastasis in prostate cancer patients. 
  Shanghai, China - 1/5/2015
• Multidisciplinary Care in Prostate Cancer. 
  Huntington Hospital - 1/3/2015
• What happens when prostate cancer metastasizies? 
  1/26/2014
• Early Detection and Management of Prostate Cancer 
  1/18/2014
• Management of BRCA-associated prostate cancer. 
  CSMC - 1/13/2014
• Molecular analysis of circulating tumor cells in prostate cancer: moving toward a liquid biopsy and personalized medicine 
  1/10/2014
• Prostate Cancer in African-American Men: What You Need to Know 
  1/8/2014
• Targeting metastasis in prostate cancer: Fyn and circulating tumor cells 
  City of Hope - 1/8/2014
• Advances in Prostate Cancer therapy 
  1/6/2014
• Clinical perspectives in Translational Research 
  1/2/2014
• CTC technology in solid tumors. 10th World Congress on Urologic Research 
  Nashville, TN - 1/21/2013
• Management of Testicular Cancer in 2013 
  1/18/2013
• Targeting the c-MET pathway: Clinical Applications 
  1/9/2013
• Advances in Systemic Therapy for Prostate and Kidney Cancer 
  Siriraj Hopital/Mahidol University, Bangkok, Thailand - 1/5/2013
• Advances in Detection and Treatment of Prostate Kidney, and Bladder Cancer 
  Guam - 1/5/2013
• Clinical Trials vs. Standard Care: Exploring New Approaches in Cancer Treatment 
  1/18/2012
• Join now to see all